Advisory Committee Discussions Will Be Key Tool In Developing REMS

Drug sponsors need not fear an advisory committee discussion about how to ensure safe use of their products, William Pullman, Chief Development Officer at Dyax, told a Jan. 13 Windhover webinar on surviving an advisory committee

More from Archive

More from Pink Sheet